Sun Pharma Advanced Research Co

147.91
-2.82
(-1.87%)
Market Cap
4,799.67 Cr
EPS
-11.93
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
472.80
52 Week Low
109.30
PB Ratio
39.23
Debt to Equity
0.12
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,734.70
#1 4,16,212.64
35.22
#1 49,887.20
12.06
#1 9,648
13.77
54.74
5,775.45
1,53,320.05
75.20
8,184.00
0.89
1,600
#1 64.53
50.68
1,442.20
1,16,474.23
24.00
26,520.70
14.17
4,155
47.38
42.46
3,227.95
1,09,248.50
58.64
10,785.70
11.59
1,656
13.54
59.06
2,424.75
1,00,039.98
49.78
10,615.60
19.57
1,942
-16.38
57.16
1,144.20
95,478.38
#1 18.06
28,905.40
12.36
5,578
1.69
43.23
2,027.95
92,584.22
32.14
20,141.50
#1 19.94
1,936
38.82
48.77
886.40
89,192.58
19.77
19,831.50
13.82
3,831
29.92
41.50
1,160.50
67,402.03
19.21
29,559.20
17.55
3,169
-10.04
52.98
30,720.55
65,279.02
48.70
6,097.20
10.80
1,201
16.01
56.63
Growth Rate
Revenue Growth
-57.95 %
Net Income Growth
73.94 %
Cash Flow Change
-520.93 %
ROE
609.31 %
ROCE
366.71 %
EBITDA Margin (Avg.)
336.00 %

Quarterly Financial Results

Quarterly Financials
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
58
34
30
20
21
18
13
15
Expenses
137
126
113
117
122
110
116
89
EBITDA
-79
-92
-83
-96
-101
-92
-103
-74
Operating Profit %
-188 %
-427 %
-432 %
-740 %
-639 %
-555 %
-800 %
-494 %
Depreciation
3
3
3
3
3
3
3
3
Interest
0
0
0
0
1
1
1
3
Profit Before Tax
-82
-95
-86
-100
-105
-96
-107
-79
Tax
0
0
0
0
0
0
0
0
Net Profit
-82
-95
-86
-100
-106
-96
-107
-80
EPS in ₹
-2.55
-2.94
-2.66
-3.07
-3.26
-2.96
-3.31
-2.45

Balance Sheet

Balance Sheet
2023
2024
Total Assets
830
515
Fixed Assets
106
108
Current Assets
455
269
Capital Work in Progress
27
44
Investments
291
2
Other Assets
407
362
Total Liabilities
830
515
Current Liabilities
179
265
Non Current Liabilities
138
124
Total Equity
513
126
Reserve & Surplus
480
93
Share Capital
33
33

Cash Flow

Cash Flow
2023
2024
Net Cash Flow
-1
5
Investing Activities
-548
392
Operating Activities
-69
-429
Financing Activities
617
42

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
68.46 %
68.46 %
68.10 %
68.10 %
69.09 %
69.09 %
69.09 %
68.22 %
65.67 %
65.67 %
65.67 %
65.67 %
65.67 %
65.67 %
65.67 %
65.67 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.30 %
3.23 %
2.64 %
2.15 %
2.23 %
DIIs
0.01 %
0.02 %
0.02 %
0.02 %
0.24 %
0.24 %
0.24 %
0.93 %
0.78 %
0.78 %
0.23 %
0.81 %
0.82 %
0.18 %
0.23 %
0.64 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
18.08 %
18.00 %
16.91 %
16.94 %
14.73 %
16.45 %
15.70 %
16.00 %
16.18 %
16.13 %
15.90 %
16.09 %
16.11 %
18.91 %
19.20 %
18.89 %
Others
13.45 %
13.52 %
14.97 %
14.94 %
15.94 %
14.22 %
14.97 %
14.85 %
17.37 %
17.42 %
18.20 %
14.13 %
14.17 %
12.60 %
12.75 %
12.58 %
No of Share Holders
0
99,454
1,10,301
94,834
95,039
93,097
94,494
93,718
96,337
1,00,807
1,01,433
1,03,990
1,02,743
1,25,184
1,28,205
1,31,034

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Closure of Trading Window3 days ago
Clarification On Price Movement4 days ago
Clarification sought from Sun Pharma Advanced Research Company Ltd4 days ago
Announcement under Regulation 30 (LODR)-Credit RatingMar 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2025
Integrated Filing (Financial)Feb 10, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. February 10 2025Feb 10, 2025
Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 10, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Closure of Trading WindowDec 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 17, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 05, 2024
Clarification Sought From Sun Pharma Advanced Research Company LtdNov 25, 2024
Clarification sought from Sun Pharma Advanced Research Company LtdNov 25, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Nov 16, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Nov 16, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2024
Clarification - Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 05, 2024
Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 04, 2024
Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 04, 2024
Board Meeting Outcome for Outcome Of Board Meeting For Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 04, 2024
Board Meeting Intimation for Approval Of Unaudited Financial Results Of The CompanyOct 25, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 15, 2024
Closure of Trading WindowSep 25, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementSep 24, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAug 14, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2024
Financial Results For The Quarter Ended June 30, 2024Aug 05, 2024
Board Meeting Outcome for Outcome Of Board Meeting For Unaudited Financial Results For The Quarter Ended June 30, 2024Aug 05, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 03, 2024
Board Meeting Intimation for The Approval Of The Financial Results Of The Company For The First Quarter Ended June 30, 2024Jul 29, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementJul 26, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementJul 26, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2024
Business Responsibility and Sustainability Reporting (BRSR)Jul 18, 2024
Notice Of 19Th Annual General Meeting Of The Company To Be Held On Monday, August 12, 2024 At 04:00 PMJul 18, 2024
Reg. 34 (1) Annual Report.Jul 18, 2024
Announcement Under Regulation 30 Of LODRJul 15, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 15, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 09, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 08, 2024
Intimation Of The 19Th Annual Annual General Meeting Of The CompanyJul 08, 2024
Closure of Trading WindowJun 26, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementMay 24, 2024

Technical Indicators

RSI(14)
Neutral
55.68
ATR(14)
Less Volatile
9.81
STOCH(9,6)
Neutral
77.71
STOCH RSI(14)
Neutral
77.54
MACD(12,26)
Bullish
3.86
ADX(14)
Strong Trend
30.47
UO(9)
Bearish
51.80
ROC(12)
Uptrend And Accelerating
17.30
WillR(14)
Neutral
-30.86

About Sun Pharma Advanced Research Co

Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers, vibozilimod for autoimmune disorders, and SCD-153 for alopecia areata. The company engages in licensing agreements and partnerships for commercialization of its products. SPARC has received FDA approvals for some of its drugs, including XELPROS for glaucoma treatment. The company was incorporated in 2006 and operates independently after demerging from Sun Pharmaceutical Industries Ltd.
Chairperson NameDilip S Shanghvi